Effect of Vitamin D Replacement on Immune Function and Cognition in MS Patients
NCT01952483 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 108
Last updated 2018-01-11
Summary
Assessing the immune activation in MS patients deficient in Vitamin D and whether Vitamin D supplementation reverse the immune activation
Evaluating whether Vitamin D deficiency result in lower cognitive performance in MS patients and the effect of Vitamin D supplementation on reversing the cognitive impairment?
Conditions
- Multiple Sclerosis (MS)
Sponsors & Collaborators
-
American University of Beirut Medical Center
lead OTHER
Principal Investigators
-
Samia J Khoury, professor · AUBMC
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-08-31
- Primary Completion
- 2017-05-01
- Completion
- 2017-06-30
Countries
- Lebanon
Study Locations
More Related Trials
-
Vitamin D3 Supplementation and the T Cell Compartment in Multiple Sclerosis (MS)
NCT00940719 ·Status: COMPLETED ·Phase: NA
-
Correlation Between Relapses in Multiple Sclerosis (MS) and Vitamin D Intake
NCT01994018 ·Status: COMPLETED
-
Role of Vitamin D in Reducing the Relapse Rate in Patients With Multiple Sclerosis
NCT01753375 ·Status: UNKNOWN ·Phase: PHASE2
-
High Dose Oral Versus Intramuscular Vitamin D3 Supplementation In Multiple Sclerosis Patients
NCT02696590 ·Status: COMPLETED ·Phase: NA
-
Vitamin D3 and the Stress-axis in MS
NCT02096133 ·Status: TERMINATED ·Phase: PHASE2
-
Efficacy of Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of MS After a Clinically Isolated Syndrome
NCT01817166 ·Status: COMPLETED ·Phase: PHASE3
-
Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis
NCT02133664 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly
NCT01198132 ·Status: COMPLETED ·Phase: PHASE2
-
A "negative"dendritic Cell-based Vaccine for the Treatment of Multiple Sclerosis: a First-in-human Clinical Trial
NCT02618902 ·Status: COMPLETED ·Phase: PHASE1
-
Physiological Effects of N-Acetyl Cysteine in Patients With Multiple Sclerosis
NCT03032601 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Impact of Vitamin A on Gene Expression, in Multiple Sclerosis Patient
NCT01407211 ·Status: UNKNOWN ·Phase: PHASE4
-
Phototherapy in Persons With Multiple Sclerosis
NCT02365259 ·Status: UNKNOWN ·Phase: PHASE1
-
Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS)
NCT02903537 ·Status: UNKNOWN ·Phase: PHASE1
-
Efficacy of Vitamin D Supplementation in Multiple Sclerosis (EVIDIMS)
NCT01440062 ·Status: TERMINATED ·Phase: PHASE2
-
The Effects of Interferon Beta Combined With Vitamin D on Relapsing Remitting Multiple Sclerosis Patients
NCT01005095 ·Status: TERMINATED ·Phase: PHASE4
-
A Phase IIa Study of Vitamin D3 Tolerogenic Dendritic Cells (tolDC) for Multiple Sclerosis
NCT07020715 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Evaluation of Nutritional Status and Fatigue in Patients With Multiple Sclerosis
NCT02008669 ·Status: COMPLETED
-
Impact of Vitamin A on Multiple Sclerosis (MS)
NCT01417273 ·Status: UNKNOWN ·Phase: PHASE4
-
Colecalciferol as an Add-on Treatment to Interferon-beta-1b for Treatment of Multiple Sclerosis (MS)
NCT01339676 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication
NCT04796584 ·Status: TERMINATED
-
Effects of Lutein Supplementation on Cognition and MPOD in Multiple Sclerosis Patients-
NCT04843813 ·Status: UNKNOWN ·Phase: NA
-
Pilot Diet Study for Multiple Sclerosis
NCT02986893 ·Status: COMPLETED ·Phase: NA
-
Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis
NCT02220244 ·Status: UNKNOWN ·Phase: PHASE3
-
Immunisation Status and Safety of Vaccines in Italian MS Patients
NCT04300868 ·Status: UNKNOWN
-
T Cell Vaccination in Patients With Progressive Multiple Sclerosis
NCT01448252 ·Status: COMPLETED ·Phase: PHASE1/PHASE2